BACKGROUND: A high prevalence of obesity has been increasingly recognized in survivors of pediatric ALL. However, longitudinal patterns of weight change during and after treatment, and associated factors, are less well elucidated. PROCEDURE: In a retrospective cohort of 83 pediatric patients with ALL diagnosed between 1985 and 2010, we examined body mass index (BMI) status at several key time points: diagnosis; end of induction; end of consolidation; every 6 months during maintenance; and yearly for up to 5 years post-treatment. RESULTS: At diagnosis, 21% were overweight (BMI = 85-94.9th percentile) or obese (BMI ≥ 95th percentile). At the end of treatment and 5 years post-treatment, approximately 40% were overweight or obese. The mean BMI z-score was 0.2 (58th percentile) at diagnosis and increased significantly during induction (Δ = 0.5, P < 0.0001). It increased again during the first 6 months of maintenance (Δ = 0.2, P < 0.01) and did not significantly change over the remainder of maintenance (BMI z-score at the end of treatment = 0.8, 79th percentile) and 5 years post-treatment (BMI z-score = 0.7, 76th percentile). High BMI z-score at diagnosis was associated with an increased risk of being overweight/obese at treatment completion (OR = 2.9, 95% CI: 1.6-5.1). Weight gain during treatment was associated with being overweight/obese 5 years post-treatment (OR = 3.8, 95% CI: 1.1-12.5). CONCLUSION: Children with ALL are at risk of becoming overweight/obese early in treatment. Increases in weight are maintained throughout treatment and beyond. Lifestyle interventions are needed targeting weight control early during treatment, particularly for patients overweight/obese at diagnosis and those who experience substantial weight gain during treatment.
BACKGROUND: A high prevalence of obesity has been increasingly recognized in survivors of pediatric ALL. However, longitudinal patterns of weight change during and after treatment, and associated factors, are less well elucidated. PROCEDURE: In a retrospective cohort of 83 pediatric patients with ALL diagnosed between 1985 and 2010, we examined body mass index (BMI) status at several key time points: diagnosis; end of induction; end of consolidation; every 6 months during maintenance; and yearly for up to 5 years post-treatment. RESULTS: At diagnosis, 21% were overweight (BMI = 85-94.9th percentile) or obese (BMI ≥ 95th percentile). At the end of treatment and 5 years post-treatment, approximately 40% were overweight or obese. The mean BMI z-score was 0.2 (58th percentile) at diagnosis and increased significantly during induction (Δ = 0.5, P < 0.0001). It increased again during the first 6 months of maintenance (Δ = 0.2, P < 0.01) and did not significantly change over the remainder of maintenance (BMI z-score at the end of treatment = 0.8, 79th percentile) and 5 years post-treatment (BMI z-score = 0.7, 76th percentile). High BMI z-score at diagnosis was associated with an increased risk of being overweight/obese at treatment completion (OR = 2.9, 95% CI: 1.6-5.1). Weight gain during treatment was associated with being overweight/obese 5 years post-treatment (OR = 3.8, 95% CI: 1.1-12.5). CONCLUSION:Children with ALL are at risk of becoming overweight/obese early in treatment. Increases in weight are maintained throughout treatment and beyond. Lifestyle interventions are needed targeting weight control early during treatment, particularly for patients overweight/obese at diagnosis and those who experience substantial weight gain during treatment.
Authors: Paul C Nathan; Vesna Jovcevska; Kirsten K Ness; Norma Mammone D'Agostino; Patricia Staneland; Stacey L Urbach; Mary Barron; Maru Barrera; Mark L Greenberg Journal: J Pediatr Date: 2006-10 Impact factor: 4.406
Authors: Bassem I Razzouk; Susan R Rose; Suradej Hongeng; Dana Wallace; Matthew P Smeltzer; Margie Zacher; Ching-Hon Pui; Melissa M Hudson Journal: J Clin Oncol Date: 2007-04-01 Impact factor: 44.544
Authors: C A Sklar; A C Mertens; A Walter; D Mitchell; M E Nesbit; M O'Leary; R Hutchinson; A T Meadows; L L Robison Journal: Med Pediatr Oncol Date: 2000-08
Authors: Allison A Hedley; Cynthia L Ogden; Clifford L Johnson; Margaret D Carroll; Lester R Curtin; Katherine M Flegal Journal: JAMA Date: 2004-06-16 Impact factor: 56.272
Authors: M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: Fang Fang Zhang; Rohit P Ojha; Kevin R Krull; Todd M Gibson; Lu Lu; Jennifer Lanctot; Wassim Chemaitilly; Leslie L Robison; Melissa M Hudson Journal: J Nutr Date: 2016-10-19 Impact factor: 4.798
Authors: Fang Fang Zhang; Edward Saltzman; Michael J Kelly; Shanshan Liu; Aviva Must; Susan K Parsons; Susan B Roberts Journal: Pediatr Blood Cancer Date: 2015-03-24 Impact factor: 3.167
Authors: Gina E Nam; Sapna Kaul; Yelena P Wu; Richard E Nelson; Jennifer Wright; Mark N Fluchel; Claire C Hacking; Anne C Kirchhoff Journal: J Cancer Surviv Date: 2015-01-10 Impact factor: 4.442
Authors: Fang Fang Zhang; Susan B Roberts; Susan K Parsons; Aviva Must; Michael J Kelly; William W Wong; Edward Saltzman Journal: J Pediatr Hematol Oncol Date: 2015-04 Impact factor: 1.289